Abbott

Cardinal Health

Johnson & Johnson

Siemens Healthineers

Stryker

GE Healthcare

Transforming neurological care with innovation

Neurostimulation Tech

SetPoint Medical is a clinical-stage healthcare company developing a novel neuroimmune modulation platform to treat chronic, inflammation-mediated autoimmune diseases. The company's core technology involves a miniaturized stimulation device surgically placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure. Once implanted, the device delivers precise vagus nerve stimulation on a preset schedule, activating anti-inflammatory and immune-restorative pathways to treat conditions like rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS).
SetPoint Medical's initial focus is on rheumatoid arthritis, a debilitating autoimmune condition affecting over 1.5 million Americans and costing nearly USD 30 billion annually to manage with existing immunosuppressive therapies and biologics. The company believes its approach could offer a potentially less immunosuppressive treatment option. SetPoint Medical is currently evaluating its RA treatment in the RESET-RA pivotal trial, a multicenter, double-blind, randomized, sham-controlled study. As of January 2023, the first patient was enrolled in Stage two of the trial.
The FDA granted SetPoint Medical's device Breakthrough Device Designation for RA patients who have an incomplete response or intolerance to multiple biologic drugs. In March 2024, the company also received Breakthrough Device Designation from the FDA for using its platform to treat relapsing-remitting multiple sclerosis (RRMS), an autoimmune disorder affecting nearly 1 million Americans. SetPoint Medical is the first to initiate a clinical trial evaluating this neuroimmune modulation approach for RRMS.
Key customers and partnerships
SetPoint Medical secured an USD 80 million preferred stock financing in January 2023, co-led by new investors Norwest Venture Partners and Viking Global Investors, along with participation from Gilmartin Capital and existing investors. The financing will support the RESET-RA trial completion, FDA submissions, and early RA indication commercialization. As part of the financing, Dr. Zack Scott from Norwest joined SetPoint Medical's board of directors.
In March 2024, SetPoint Medical was accepted into the FDA's Total Product lifecycle (TPLC) Advisory Program Pilot to expedite the development and patient access of its neuroimmune modulation platform for RRMS treatment. This program facilitates earlier interactions with providers, payors, patients, and strategic advice from the FDA's Center for Devices and Radiological Health.

The official LinkedIn page for the University of Nebraska, the only public research university in the state of Nebraska.

The largest university in the state, the University of Nebraska at Lincoln offers academic programs and research that have long placed it at the forefront of education.  For example, University of Nebraska is one of the first universities to establish a major in Digital Humanities, offered through the English Department.  In the same department, graduate students may undertake UNL’s prestigious MFA program in Creative Writing, which has leading writers among its faculty and is also responsible for founding one of the country’s most respected university literary publications.  On the fine arts end of things, UNL boasts top museums and galleries with collections by some of the world’s most revered artists. UNL also has a natural history museum, which features fossils and other types of ancient excavations.  Additional areas of study include: *Agricultural Sciences *Architecture *Education *Engineering *Law *Liberal Arts and Humanities *Performing Arts *Mass Communications UNL has long been distinguished for its research activity as well, conducting valuable research in a variety of scientific and other fields.

Since its founding in 1944, EasterSeals has had one mission: ensuring that children and adults with disabilities have equal opportunities to live, learn, work and play.  Through the years Easter Seals has been continually developing new programs and innovative approaches to meet the specific needs of its clients.  One of Easter Seals’ most enduring programs has provided a summer camp experience for children with disabilities for more than 60 years. Easter Seals currently serves hundreds of children every summer in our camping program at Agassiz Village in Maine.  Through the Youth Leadership program, Easter Seals also offers opportunities for young people with disabilities to discover their personal abilities and skills. Service learning activities help generate feelings of importance and self-worth, while encouraging them to become forces for change in their communities.  In 1988, Easter Seals recognized the potential benefits that technology holds for children and adults with disabilities. Its assistive technology program began with a few donated computers and one specialist. Today, the program has more than 20 specialists and utilizes a wide array of software, hardware and adaptive devices.  Easter Seals is now a national leader in using technology to expand independence for people with disabilities at home, in school and in the workplace.  Numerous programs help people access the assistive technology they need. At the Assistive Technology Regional Centers, people with disabilities can see, try out and borrow devices in order to make more informed decisions about technology that will meet their needs.  The Massachusetts Assistive Technology Loan Program provides access to low-interest cash loans for the purchase of assistive devices and services that will improve the quality of life for people with disabilities. Our Long-Term Device Loan Program provides people with assistive devices that cost less than $500. The devices are available free of charge to qualified Massachusetts residents with disabilities and their families.  Easter Seals Rehabilitation Services offers physical, occupational and speech therapy to people in homes, schools, nursing homes, day care centers and clinics.  The Easter Seals Job Training and Employment program helps people with disabilities develop the skills they need in order to get and keep jobs in today’s competitive workplace. The program offers individualized vocational rehabilitation, job training and employment services to students and adults.  Easter Seals staff members also answer thousands of questions every year through a disability resource information center. And advocates work to help state legislators and government officials understand and meet all the needs of men, women and children with disabilities.  In 2014, Easter Seals services benefited more than 26,000 Massachusetts residents with disabilities, their families, teachers and employers.  Easter Seals and its affiliate organizations are 501(c)(3) nonprofit organizations.

Howard University provides education to African-American students. It offers undergraduate, graduate, and doctoral programs, including law, medicine, and pharmaceutical studies. It is influenced by the political and cultural environment.

Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes. The company developing an end-to-end type 1 diabetes management system using a simple design, cloud connectivity, and human-centered automation. It optimizes the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. Biofoot Biomedical ’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. By employing data-driven intelligence across an integrated device ecosystem, they are transforming diabetes care with a fully comprehensive digital drug delivery platform experienced as a service.

Alere Inc., formerly Inverness Medical Innovations, Inc., provides diagnostics and health management solutions. The Company's products and services are focused on infectious disease, cardiology, oncology, drugs of abuse and women's health. Its brands range from over-the-counter tests to lab-based diagnostics to integrated home monitoring solutions. The Company's brands include Acceava Mono cassette, Alere Home Monitoring, AtheNA Multi-Lyte Test System, BinaxNOW, Cholestech LDX, Clearview iFOB Complete, Determine HBsAg, DoubleCheckGold and ImmunoComb. The Company has operations in North America, Europe and Middle East, Asia Pacific, and Latin America and Africa.

SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating patients with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. SetPoint Medical’s platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy.

Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Abbott is engaged in pharmaceuticals and manufacturing healthcare products. It developed the first HIV blood-screening test. Its product portfolio includes Norvir, a treatment for HIV, Synthroid, a synthetic thyroid hormone, Depakote, an anticonvulsant drug, and Humira, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and more.

<div> Abbott Laboratories (NYSE: ABT) is a leading, diversified, diagnostic system and medical device manufacturer. It is among the 10 largest medical device manufacturers by revenue, based on corresponding segment sales in 2023. In 2013, the company spun off its branded pharmaceutical business into a new entity named AbbVie, allowing the company to focus on its core strengths relating to diagnostic and medical devices. Abbott generated USD 40.1 billion in sales in 2023. The company's Diagnostic Products segment includes a range of rapid test kits and laboratory diagnostic systems focused on infectious diseases, cardiometabolic diseases, and toxicology. Abbott's Medical Devices segment offers a broad range of medical devices for diabetes care, vascular, rhythm management, electrophysiology, heart failure, and neuromodulation. The company&rsquo;s infant and follow-on formula and adult nutritional products are sold under its Nutritional Products segment. Abbott also houses a portfolio of branded generic pharmaceuticals under its Established Pharmaceutical Products segment. These products are focused on gastroenterology, women's health, cardiology, metabolism, and pain and central nervous system disorders, and are sold exclusively outside the US. International markets accounted for ~61% of Abbott&rsquo;s 2023 sales, while the US&mdash;being the largest standalone market&mdash;accounted for the remainder. Diabetes care remains a focus area for the company, particularly with its continuous glucose monitoring (CGM) device, FreeStyle Libre, being a potential USD 10 billion opportunity over the long term. It expects an 8% to 10% organic sales growth target for 2024, excluding Covid-19 test sales. Abbott Laboratories has also targeted a 30% reduction in absolute Scope 1 and 2 carbon emissions by 2030, compared with its 2018 baseline. </div>

Abbott’s FreeStyle Libre® 2 Now Reimbursed for Children and Adults Living with Diabetes in Alberta

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

Sports Tech

Technology solution providers for sports venues, which includes solutions for stadium management, connectivity and entertainment, and video assistant referee (VAR) technology

Platforms and devices that aid the training process and/or measure player statistics and other metrics, such as health and movement data, to improve player performance

Platforms that assists the management of teams, leagues, tournaments, and other sporting events

Providers of sports data for other sports-related platforms

Online media platforms that distribute sports-related content

Online sports betting platforms and platforms where virtual teams composed of proxies of real players of a professional sport compete based on player performance in actual games

Companies that develop apparel products equipped with technology to track and improve performance

Platforms that enable fans to engage with sports brands and other fans, and developers of solutions such as audience behavior and sentiment analytics, and audience engagement

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

Abbott, a healthcare company, has agreed to acquire chronic care management company Bigfoot Biomedical, with the deal expected to be completed in Q3 2023. This acquisition follows a partnership between the two companies in 2017 and subsequent investments by Abbott in Bigfoot. Bigfoot developed the Bigfoot Unity system, a smart insulin system that uses connected insulin pen caps and continuous glucose monitoring data to provide insulin dosing recommendations. The system was initially designed to work with Abbott's FreeStyle Libre technology and includes a mobile app for users and a cloud-based portal for healthcare providers. The companies aim to advance tech-driven solutions for personalized diabetes management.

Abbott

Featured Industries

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless